Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

ProKidney Corp., a clinical-stage biotechnology, engages in developing cellular therapy candidates. It is developing Renal Autologous Cell Therapy, an autologous homologous cell admixture that is in a Phase III development program, as well as Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease; and Phase I clinical trial for patients with congenital anomalies of the kidney and urinary tract. The company was founded in 2015 and is headquartered in Winston-Salem, North Carolina.

ProKidney Corp.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

WINSTON-SALEM, N.C., AUG. 12, 2025 (GLOBE NEWSWIRE) -- PROKIDNEY CORP. (NASDAQ: PROK) (PROKIDNEY OR THE COMPANY"), A LEADING LATE CLINICAL-STAGE CELL THERAPEUTICS COMPANY FOCUSED ON CHRONIC KIDNEY DISEASE (CKD), TODAY REPORTED FINANCIAL RESULTS FOR THE SECOND QUARTER ENDED JUNE 30, 2025, AND PROVIDED REGULATORY AND CLINICAL UPDATES.

PROKIDNEY REPORTS SECOND QUARTER 2025 FINANCIAL RESULTS AND PROVIDES REGULATORY AND CLINICAL UPDATES

WINSTON-SALEM, N.C., JULY 15, 2025 (GLOBE NEWSWIRE) -- PROKIDNEY CORP. (NASDAQ: PROK) (PROKIDNEY OR THE COMPANY"), A LEADING LATE CLINICAL-STAGE CELLULAR THERAPEUTICS COMPANY FOCUSED ON CHRONIC KIDNEY DISEASE (CKD), TODAY ANNOUNCED CONFIRMATION OF ALIGNMENT WITH THE U.S. FOOD AND DRUG ADMINISTRATION (FDA) ON THE ACCELERATED APPROVAL PATHWAY FOR RILPARENCEL. RILPARENCEL IS AN AUTOLOGOUS CELLULAR THERAPY THAT RECEIVED REGENERATIVE MEDICINE ADVANCED THERAPY (RMAT) DESIGNATION FROM THE FDA AND CURRENTLY IS BEING EVALUATED IN THE ONGOING PHASE 3 REGEN-006 (PROACT 1) TRIAL TO DEMONSTRATE THE THERAPY'S POTENTIAL TO PRESERVE KIDNEY FUNCTION IN PATIENTS WITH ADVANCED CKD AND TYPE 2 DIABETES.

PROKIDNEY ANNOUNCES ALIGNMENT WITH THE FDA ON THE ACCELERATED APPROVAL PATHWAY FOR RILPARENCEL

WINSTON-SALEM, N.C., JULY 09, 2025 (GLOBE NEWSWIRE) -- PROKIDNEY CORP. (NASDAQ: PROK) (PROKIDNEY OR THE COMPANY), A LEADING LATE CLINICAL-STAGE CELLULAR THERAPEUTICS COMPANY FOCUSED ON CHRONIC KIDNEY DISEASE (CKD), TODAY ANNOUNCED THAT SENIOR MEMBERS OF THE MANAGEMENT TEAM WILL BE PARTICIPATING IN THE UPCOMING H.C. WAINWRIGHT 4TH ANNUAL KIDNEY VIRTUAL CONFERENCE:

PROKIDNEY TO PARTICIPATE IN THE H.C. WAINWRIGHT 4TH ANNUAL KIDNEY VIRTUAL CONFERENCE

WINSTON-SALEM, N.C., JULY 08, 2025 (GLOBE NEWSWIRE) -- PROKIDNEY CORP. (NASDAQ: PROK) (PROKIDNEY OR THE COMPANY"), A LEADING LATE CLINICAL-STAGE CELLULAR THERAPEUTICS COMPANY FOCUSED ON CHRONIC KIDNEY DISEASE (CKD), TODAY REPORTED STATISTICALLY SIGNIFICANT AND CLINICALLY MEANINGFUL POSITIVE TOPLINE RESULTS FROM THE FULL GROUP 1 MODIFIED INTENT-TO-TREAT (MITT) POPULATION OF THE PHASE 2 REGEN-007 TRIAL EVALUATING RILPARENCEL IN PATIENTS WITH CKD AND DIABETES. RILPARENCEL IS AN AUTOLOGOUS CELLULAR THERAPY THAT HAS RECEIVED REGENERATIVE MEDICINE ADVANCED THERAPY (RMAT) DESIGNATION FROM THE U.S. FOOD & DRUG ADMINISTRATION (FDA) AND IS CURRENTLY BEING EVALUATED IN THE ONGOING PHASE 3 REGEN-006 (PROACT 1) TRIAL TO DEMONSTRATE THE THERAPY'S POTENTIAL TO PRESERVE KIDNEY FUNCTION IN PATIENTS WITH ADVANCED CKD AND TYPE 2 DIABETES.

PROKIDNEY REPORTS STATISTICALLY AND CLINICALLY SIGNIFICANT TOPLINE RESULTS FOR THE PHASE 2 REGEN-007 TRIAL EVALUATING RILPARENCEL IN PATIENTS WITH CHRONIC KIDNEY DISEASE AND DIABETES

WINSTON-SALEM, N.C., JULY 01, 2025 (GLOBE NEWSWIRE) -- PROKIDNEY CORP. (NASDAQ: PROK) (PROKIDNEY OR THE COMPANY"), A LEADING LATE CLINICAL-STAGE CELLULAR THERAPEUTICS COMPANY FOCUSED ON CHRONIC KIDNEY DISEASE (CKD), TODAY ANNOUNCED THE COMPLETION OF THE DOMESTICATION PROCESS TO CHANGE THE JURISDICTION OF INCORPORATION OF THE COMPANY FROM THE CAYMAN ISLANDS TO DELAWARE. THE DOMESTICATION WAS APPROVED BY SHAREHOLDERS OF THE COMPANY AT ITS ANNUAL GENERAL MEETING HELD ON MAY 29, 2025. EFFECTIVE AS OF JULY 1, 2025, EACH (I) CLASS A ORDINARY SHARE AUTOMATICALLY CONVERTED INTO ONE SHARE OF CLASS A COMMON STOCK OF PROKIDNEY CORP., A DELAWARE CORPORATION AND (II) EACH CLASS B ORDINARY SHARE AUTOMATICALLY CONVERTED INTO ONE SHARE OF CLASS B COMMON STOCK OF PROKIDNEY. PROKIDNEY COMMON STOCK WILL BEGIN TRADING ON JULY 2, 2025, AND THE COMPANY'S TRADING SYMBOL ON THE NASDAQ STOCK MARKET WILL REMAIN UNCHANGED AS "PROK." THE COMPANY'S CUSIP NUMBER RELATING TO ITS CLASS A COMMON STOCK CHANGED TO 74291D 104. THE COMPANY DOES NOT ANTICIPATE ANY IMPACT TO DAY-TO-DAY BUSINESS OPERATIONS AS A RESULT OF THE DOMESTICATION.

PROKIDNEY CORP. COMPLETES DOMESTICATION FROM THE CAYMAN ISLANDS TO DELAWARE

WINSTON-SALEM, N.C., MAY 12, 2025 (GLOBE NEWSWIRE) -- PROKIDNEY CORP. (NASDAQ: PROK) (PROKIDNEY OR THE COMPANY"), A LEADING LATE CLINICAL-STAGE CELLULAR THERAPEUTICS COMPANY FOCUSED ON CHRONIC KIDNEY DISEASE (CKD), TODAY REPORTED FINANCIAL RESULTS AND BUSINESS HIGHLIGHTS FOR THE FIRST QUARTER ENDED MARCH 31, 2025.

PROKIDNEY REPORTS FIRST QUARTER 2025 FINANCIAL RESULTS AND BUSINESS HIGHLIGHTS

WINSTON-SALEM, N.C., MARCH 17, 2025 (GLOBE NEWSWIRE) -- PROKIDNEY CORP. (NASDAQ: PROK) (PROKIDNEY), A LEADING LATE CLINICAL-STAGE CELLULAR THERAPEUTICS COMPANY FOCUSED ON CHRONIC KIDNEY DISEASE (CKD), TODAY ANNOUNCED FINANCIAL RESULTS AND BUSINESS HIGHLIGHTS FOR THE YEAR ENDED DECEMBER 31, 2024.

PROKIDNEY REPORTS FULL YEAR 2024 FINANCIAL RESULTS AND BUSINESS HIGHLIGHTS

NEW YORK , JAN. 31, 2025 /PRNEWSWIRE/ -- KUEHN LAW, PLLC, A SHAREHOLDER LITIGATION LAW FIRM, IS INVESTIGATING WHETHER CERTAIN OFFICERS AND DIRECTORS OF PROKIDNEY CORP. (NASDAQ: PROK) BREACHED THEIR FIDUCIARY DUTIES TO SHAREHOLDERS. THE INVESTIGATION CONCERNS POTENTIAL SELF-DEALING.

KUEHN LAW ENCOURAGES INVESTORS OF PROKIDNEY CORP. TO CONTACT LAW FIRM

WINSTON-SALEM, N.C., NOV. 26, 2024 (GLOBE NEWSWIRE) -- PROKIDNEY CORP. (NASDAQ: PROK)(PROKIDNEY), A LATE CLINICAL-STAGE BIOTECH COMPANY FOCUSED ON THE DEVELOPMENT OF A FIRST-IN-CLASS CELL THERAPY CANDIDATE FOR CHRONIC KIDNEY DISEASE (CKD), TODAY ANNOUNCED THAT SENIOR MEMBERS OF THE MANAGEMENT TEAM WILL BE PARTICIPATING IN THE FOLLOWING TWO UPCOMING HEALTHCARE CONFERENCES IN DECEMBER:

PROKIDNEY TO PARTICIPATE IN TWO UPCOMING CONFERENCES: EVERCORE HEALTHCONX CONFERENCE AND THE CITI GLOBAL HEALTHCARE CONFERENCE

WINSTON-SALEM, N.C., NOV. 12, 2024 (GLOBE NEWSWIRE) -- PROKIDNEY CORP. (NASDAQ: PROK) (PROKIDNEY OR THE COMPANY"), A LEADING LATE CLINICAL-STAGE CELLULAR THERAPEUTICS COMPANY FOCUSED ON CHRONIC KIDNEY DISEASE (CKD), TODAY REPORTED FINANCIAL RESULTS FOR THE THIRD QUARTER ENDED SEPTEMBER 30, 2024, AND GAVE SEVERAL REGULATORY AND CLINICAL DEVELOPMENT UPDATES.

ProKidney Corp.

PROK

Price

Financials Overview

Financial Reports

No items found.

Press Releases

ProKidney Corp.

PROK.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financials Overview

Financial Reports

No items found.

Press Releases

PROK